| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a9e9ce63eb0bbf3658453fb50a6d9b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate |
1995-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0cc6b3dfcd1807b90bb349082db05f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbc02e7e19b5d54f61b5b447aebd255e |
| publicationDate |
1995-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0669400-A1 |
| titleOfInvention |
Method of diagnosing cancer or precancerous state by analysis of IRF-1-specific RNA |
| abstract |
The present invention relates to a method of diagnosing cancer, precancerous state, and susceptibility to other forms of diseases, by use of a molecular marker, interferon-regulatory factor-1 (IRF-1). The method is characterized in that IRF- 1-specific RNA is analysed in a sample obtained from blood or other biopsy material, preferably by reverse transcription/polymerase chain reaction. n The invention is based on the unexpected finding that a novel mechanism of inactivation of the tumor suppressor gene IRF- 1 plays a crucial role e.g. in hematopoietic malignancies. An unusual exon skipping leads to RNA molecules which lack exon 2 or exons 2 and 3. The relative amounts of full-length RNA and shortened RNA molecules are significantly different in samples obtained from tumor patients as compared to healthy donors. |
| priorityDate |
1994-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |